ROCHE HLDG LTD SPONS Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (30)

Latest Posts

About This Stock More About This Stock
E Exotic Markets
Article By: Vivian Lewis
Tuesday, May 15, 2018 10:38 AM EDT
I am very fond of exotic stocks like Czech ones because they have growth levels unreachable in most developed stock markets where hundreds of analysts are looking for performance.
In this article: AEF, CCJ, MDT, RBS, SQM, SAN, FAX, FCO, AZSEY, DGRLY, NPSNY, RHHBY, RNSHF, SLFPY, TCEHY, TRYIY, HOLI, VRGDF, MZOR
Read
Busted Biotech Stocks: Where Do We Go From Here?
Article By: Rod Raynovich
Wednesday, April 4, 2018 1:39 PM EDT
Biotech stocks are really being hurt by overall negative market sentiment and a de-risking mentality rather than industry specific news.
In this article: IBB, XBI, BMY, RHHBY, FBIOX, CELG, GILD, ABBV, BLUE, REGN
Read
E Tech Reversal
Article By: Vivian Lewis
Thursday, March 22, 2018 8:54 AM EDT
While the focus of world attention is on the collapse of the most crowded trade on global stock markets, tech, other businesses continue with news, deals, financings, and matters to report.
In this article: MFGP, ALV, BP, BUD, CZZ, GBX, GSK, KUBTY, NVO, SLB, VOD, CH, FAX, FCO, AZSEY, FANUY, SAXPY, SLFPY, MELI, TEVA, FB, HPE, VRGDF, MZOR, ZYME, RHHBY
Read
Biotechs Buffeted By Macro News But Should Continue To Outperform
Article By: Rod Raynovich
Tuesday, March 6, 2018 12:04 PM EDT
Biotechs outperform in 2018 having recovered most of their losses from last week’s volatility caused by dire tariff talk and higher interest rates, raising concerns about the impact on global growth.
In this article: AMGN, RHHBY, GILD, CELG, JUNO, KPTI, BLUE, XBI
Read
Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss
Article By: Zacks Investment Research
Wednesday, February 28, 2018 7:00 PM EDT
Mylan N.V. reported mixed results for fourth-quarter 2017 as EpiPen sales declined. Adjusted earnings of $1.43 per share beat the Zacks Consensus Estimate of $1.41 but was down from $1.57 reported in the year-ago quarter.
In this article: MYL Also: GSK, RHHBY, TEVA
Read

PARTNER HEADLINES

Latest Tweets for $RHHBY

No tweets yet!